VectorBuilder
@vectorbuilder.bsky.social
VectorBuilder is a global leader in gene delivery technologies.
Excited to highlight new work from the @roychoudhurilab.bsky.social showing control of BACH2 dosage can improve adoptive T cell therapies.
Low-dose BACH2 promotes T cell persistence without compromising effector function, enhancing antitumor activity. A step forward for personalized immunotherapy.
Low-dose BACH2 promotes T cell persistence without compromising effector function, enhancing antitumor activity. A step forward for personalized immunotherapy.
Thrilled to share our latest work: Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy - now online in Nature Immunology. Led by Alberto Conti, Alex Evans and Teresa von Linde in the lab. www.nature.com/articles/s41...
February 18, 2026 at 4:59 PM
Excited to highlight new work from the @roychoudhurilab.bsky.social showing control of BACH2 dosage can improve adoptive T cell therapies.
Low-dose BACH2 promotes T cell persistence without compromising effector function, enhancing antitumor activity. A step forward for personalized immunotherapy.
Low-dose BACH2 promotes T cell persistence without compromising effector function, enhancing antitumor activity. A step forward for personalized immunotherapy.
Still looking for a card for tomorrow?
Free downloadable geeky Valentine’s, right this way 🧪💘
Download here: hubs.la/Q041jHGJ0
Free downloadable geeky Valentine’s, right this way 🧪💘
Download here: hubs.la/Q041jHGJ0
February 13, 2026 at 12:18 PM
Still looking for a card for tomorrow?
Free downloadable geeky Valentine’s, right this way 🧪💘
Download here: hubs.la/Q041jHGJ0
Free downloadable geeky Valentine’s, right this way 🧪💘
Download here: hubs.la/Q041jHGJ0
🧬 Studying how disease begins matters. Our next Gene Delivery Seminar is one week away. Sign up to learn how early genetic events underlying acute lymphoblastic leukemia are investigated in vivo.
🧬 Did you know acute lymphoblastic leukemia is the most common childhood cancer? But how does it begin?
Join our next Gene Delivery Seminar with @jamesrallen.bsky.social, @hhmi-science.bsky.social Hanna Gray Fellow and incoming faculty at @mayoclinic.org, on February 19.
Join our next Gene Delivery Seminar with @jamesrallen.bsky.social, @hhmi-science.bsky.social Hanna Gray Fellow and incoming faculty at @mayoclinic.org, on February 19.
February 13, 2026 at 12:06 PM
🧬 Studying how disease begins matters. Our next Gene Delivery Seminar is one week away. Sign up to learn how early genetic events underlying acute lymphoblastic leukemia are investigated in vivo.
On this #InternationalDayofWomenandGirlsinScience, we celebrate the women and girls whose curiosity and creativity drive discovery. Supporting access and opportunity in science matters because diverse perspectives strengthen research and fuel innovation for everyone.
February 11, 2026 at 3:09 PM
On this #InternationalDayofWomenandGirlsinScience, we celebrate the women and girls whose curiosity and creativity drive discovery. Supporting access and opportunity in science matters because diverse perspectives strengthen research and fuel innovation for everyone.
🎉 Our Annual Survey winners are here!
Huge thanks to everyone who shared feedback—and congrats to our winners 🏆
More info landing in your inbox soon 👀📩
Huge thanks to everyone who shared feedback—and congrats to our winners 🏆
More info landing in your inbox soon 👀📩
February 11, 2026 at 11:05 AM
🎉 Our Annual Survey winners are here!
Huge thanks to everyone who shared feedback—and congrats to our winners 🏆
More info landing in your inbox soon 👀📩
Huge thanks to everyone who shared feedback—and congrats to our winners 🏆
More info landing in your inbox soon 👀📩
Learn more here: en.vectorbuilder.com/products-ser...
February 10, 2026 at 7:11 PM
Learn more here: en.vectorbuilder.com/products-ser...
Over the past few weeks, we’ve focused on IVT RNA design optimization and LNP-RNA delivery.
This week, we’re closing the series with therapeutic IVT RNA, covering clinical applications from genome editing and CAR-T to mRNA cancer therapies.
Swipe through to explore.
This week, we’re closing the series with therapeutic IVT RNA, covering clinical applications from genome editing and CAR-T to mRNA cancer therapies.
Swipe through to explore.
February 10, 2026 at 7:11 PM
Over the past few weeks, we’ve focused on IVT RNA design optimization and LNP-RNA delivery.
This week, we’re closing the series with therapeutic IVT RNA, covering clinical applications from genome editing and CAR-T to mRNA cancer therapies.
Swipe through to explore.
This week, we’re closing the series with therapeutic IVT RNA, covering clinical applications from genome editing and CAR-T to mRNA cancer therapies.
Swipe through to explore.
Want a printable/shareable version of the cards?
Check out our cards here: hubs.la/Q041jJqD0
Check out our cards here: hubs.la/Q041jJqD0
February 9, 2026 at 5:46 PM
Want a printable/shareable version of the cards?
Check out our cards here: hubs.la/Q041jJqD0
Check out our cards here: hubs.la/Q041jJqD0
Do you need a Valentine’s Day card for your lab mate or loved one? We made a few you can download, perfect for lab benches, desks, and sharing a little science love. 🧬💘
February 9, 2026 at 5:46 PM
Do you need a Valentine’s Day card for your lab mate or loved one? We made a few you can download, perfect for lab benches, desks, and sharing a little science love. 🧬💘
🎉 Annual Survey winners announced Wednesday, February 11 🎉
Keep an eye out—you might see your name!
Thank you to everyone who shared feedback and helped shape what’s next for VectorBuilder.
Keep an eye out—you might see your name!
Thank you to everyone who shared feedback and helped shape what’s next for VectorBuilder.
February 6, 2026 at 10:03 AM
🎉 Annual Survey winners announced Wednesday, February 11 🎉
Keep an eye out—you might see your name!
Thank you to everyone who shared feedback and helped shape what’s next for VectorBuilder.
Keep an eye out—you might see your name!
Thank you to everyone who shared feedback and helped shape what’s next for VectorBuilder.
🧬 How do diseases initiate at the genetic level?
Our next Gene Delivery Seminar highlights how early genetic events are studied in vivo, with relevance to cancer biology and beyond.
Sign up now: us06web.zoom.us/webinar/regi...
Our next Gene Delivery Seminar highlights how early genetic events are studied in vivo, with relevance to cancer biology and beyond.
Sign up now: us06web.zoom.us/webinar/regi...
February 5, 2026 at 4:11 PM
🧬 How do diseases initiate at the genetic level?
Our next Gene Delivery Seminar highlights how early genetic events are studied in vivo, with relevance to cancer biology and beyond.
Sign up now: us06web.zoom.us/webinar/regi...
Our next Gene Delivery Seminar highlights how early genetic events are studied in vivo, with relevance to cancer biology and beyond.
Sign up now: us06web.zoom.us/webinar/regi...
Read more here: en.vectorbuilder.com/products-ser...
February 5, 2026 at 4:09 PM
Read more here: en.vectorbuilder.com/products-ser...
Last week, we highlighted how IVT RNA design optimization improves R&D performance. This week, we’re focusing on LNP-RNA delivery and how formulation and antibody conjugation enhance outcomes.
More next week on clinical applications!
More next week on clinical applications!
February 5, 2026 at 4:09 PM
Last week, we highlighted how IVT RNA design optimization improves R&D performance. This week, we’re focusing on LNP-RNA delivery and how formulation and antibody conjugation enhance outcomes.
More next week on clinical applications!
More next week on clinical applications!
On World Cancer Day, we honor patients and their families while recognizing the significant advances in cancer research and the work that remains to be done. That’s why we support scientists working to turn discoveries into real impact for all patients.
February 4, 2026 at 3:46 PM
On World Cancer Day, we honor patients and their families while recognizing the significant advances in cancer research and the work that remains to be done. That’s why we support scientists working to turn discoveries into real impact for all patients.
Congratulations to Ilia Kurochkin and the @cellreprolab.bsky.social on their publication introducing REPROcode, a platform for combinatorial transcription factor screening that enables controlled immune cell reprogramming toward distinct lineages.
We’re excited to share that our recent paper, “A combinatorial transcription factor screening platform for immune cell reprogramming”, has been selected for the cover of the January issue of Cell Systems!✨
February 2, 2026 at 2:58 PM
Congratulations to Ilia Kurochkin and the @cellreprolab.bsky.social on their publication introducing REPROcode, a platform for combinatorial transcription factor screening that enables controlled immune cell reprogramming toward distinct lineages.
This is your final opportunity to let us know what’s working and where we can improve; our annual survey closes on January 31!
Your feedback directly informs the development of future VectorBuilder tools and improvements. Complete the survey for a chance to win up to $1,000 in store credit.
Your feedback directly informs the development of future VectorBuilder tools and improvements. Complete the survey for a chance to win up to $1,000 in store credit.
📣 Share Your Thoughts and Boost Your Research!
Our Annual User Survey is now live, and we’d love to hear from you. Your feedback directly helps us improve the tools, services, and support that power your research, including VectorBee upgrades.
Our Annual User Survey is now live, and we’d love to hear from you. Your feedback directly helps us improve the tools, services, and support that power your research, including VectorBee upgrades.
January 30, 2026 at 4:36 PM
This is your final opportunity to let us know what’s working and where we can improve; our annual survey closes on January 31!
Your feedback directly informs the development of future VectorBuilder tools and improvements. Complete the survey for a chance to win up to $1,000 in store credit.
Your feedback directly informs the development of future VectorBuilder tools and improvements. Complete the survey for a chance to win up to $1,000 in store credit.
Register here: us06web.zoom.us/webinar/regi...
Welcome! You are invited to join a webinar: Gene Delivery Seminar: James Allen. After registering, you will receive a confirmation email about joining the webinar.
Leveraging zebrafish to discover cancer initiation in pediatric leukemia
Using mosaic screening approaches in transgenic zebrafish to rapidly interrogate and unravel complex gene networks involved in...
us06web.zoom.us
January 29, 2026 at 3:06 PM
Register here: us06web.zoom.us/webinar/regi...
🧬 Did you know acute lymphoblastic leukemia is the most common childhood cancer? But how does it begin?
Join our next Gene Delivery Seminar with @jamesrallen.bsky.social, @hhmi-science.bsky.social Hanna Gray Fellow and incoming faculty at @mayoclinic.org, on February 19.
Join our next Gene Delivery Seminar with @jamesrallen.bsky.social, @hhmi-science.bsky.social Hanna Gray Fellow and incoming faculty at @mayoclinic.org, on February 19.
January 29, 2026 at 3:06 PM
🧬 Did you know acute lymphoblastic leukemia is the most common childhood cancer? But how does it begin?
Join our next Gene Delivery Seminar with @jamesrallen.bsky.social, @hhmi-science.bsky.social Hanna Gray Fellow and incoming faculty at @mayoclinic.org, on February 19.
Join our next Gene Delivery Seminar with @jamesrallen.bsky.social, @hhmi-science.bsky.social Hanna Gray Fellow and incoming faculty at @mayoclinic.org, on February 19.
CRISPR therapies are no longer a pipe dream. As genome editing moves into the clinic, delivery is now the real challenge.
In her latest article, Dr. Connie Rich explores how delivery design shapes which CRISPR therapies reach patients safely and at scale.
Read here: www.calameo.com/read/0061133...
In her latest article, Dr. Connie Rich explores how delivery design shapes which CRISPR therapies reach patients safely and at scale.
Read here: www.calameo.com/read/0061133...
EBR Winter 2026
Weclome to EBR Winter 2026! Featuring articles on CRISPR Screening, Vaccines, Biosimilars and Biologics. Richter BioLogics showcases its CDMO services in its Supplement!
www.calameo.com
January 28, 2026 at 4:58 PM
CRISPR therapies are no longer a pipe dream. As genome editing moves into the clinic, delivery is now the real challenge.
In her latest article, Dr. Connie Rich explores how delivery design shapes which CRISPR therapies reach patients safely and at scale.
Read here: www.calameo.com/read/0061133...
In her latest article, Dr. Connie Rich explores how delivery design shapes which CRISPR therapies reach patients safely and at scale.
Read here: www.calameo.com/read/0061133...
Read more about it here: en.vectorbuilder.com/products-ser...
January 27, 2026 at 5:48 PM
Read more about it here: en.vectorbuilder.com/products-ser...
Have you met VectorBuilder’s end-to-end IVT RNA platform? This week, we’re highlighting how our IVT RNA design optimization strategies support performance and consistency throughout the R&D process.
Stay tuned next week as we explore LNP delivery!
Stay tuned next week as we explore LNP delivery!
January 27, 2026 at 5:46 PM
Have you met VectorBuilder’s end-to-end IVT RNA platform? This week, we’re highlighting how our IVT RNA design optimization strategies support performance and consistency throughout the R&D process.
Stay tuned next week as we explore LNP delivery!
Stay tuned next week as we explore LNP delivery!
A reminder that our Annual User Survey is still open, but not for long. Your feedback plays a key role in shaping future VectorBuilder improvements.
Take a few minutes to share your experience and enter to win store credit prizes up to $1,000.
Take a few minutes to share your experience and enter to win store credit prizes up to $1,000.
📣 Share Your Thoughts and Boost Your Research!
Our Annual User Survey is now live, and we’d love to hear from you. Your feedback directly helps us improve the tools, services, and support that power your research, including VectorBee upgrades.
Our Annual User Survey is now live, and we’d love to hear from you. Your feedback directly helps us improve the tools, services, and support that power your research, including VectorBee upgrades.
January 23, 2026 at 3:54 PM
A reminder that our Annual User Survey is still open, but not for long. Your feedback plays a key role in shaping future VectorBuilder improvements.
Take a few minutes to share your experience and enter to win store credit prizes up to $1,000.
Take a few minutes to share your experience and enter to win store credit prizes up to $1,000.
If tissue clearing or whole-sample imaging is something you’re curious about, we hope you can join us.
Register here: us06web.zoom.us/webinar/regi...
Register here: us06web.zoom.us/webinar/regi...
Welcome! You are invited to join a webinar: Gene Delivery Seminar: Cristina Martinez Gonzalez. After registering, you will receive a confirmation email about joining the webinar.
This seminar will introduce novel tissue-clearing strategies and the key considerations involved in selecting the most suitable approach for different samples and research objectives. By exploring how...
us06web.zoom.us
January 22, 2026 at 2:30 PM
If tissue clearing or whole-sample imaging is something you’re curious about, we hope you can join us.
Register here: us06web.zoom.us/webinar/regi...
Register here: us06web.zoom.us/webinar/regi...
Our first Gene Delivery Seminar of the year kicks off TODAY! Dr. @cristina-mtz-glz.bsky.social will share practical insights on choosing tissue-clearing approaches and utilizing advanced imaging to visualize intact samples in 3D.
Interested in tissue-clearing techniques to study intact samples in 3D? Catch Dr. Cristina Martinez Gonzalez's talk (@cristina-mtz-glz.bsky.social) as she introduces novel tissue-clearing strategies & key considerations for selecting the right protocol for different samples & research objectives.
January 22, 2026 at 2:30 PM
Our first Gene Delivery Seminar of the year kicks off TODAY! Dr. @cristina-mtz-glz.bsky.social will share practical insights on choosing tissue-clearing approaches and utilizing advanced imaging to visualize intact samples in 3D.
You spoke. We listened. New Updates. 🧬
Since launching in 2024, VectorBee has continued to expand its tools for sequence analysis, vector design, and molecular cloning. If you haven’t used our FREE software yet, check out why scientists are buzzing about it: www.vectorbee.com/en/ 🐝
Since launching in 2024, VectorBee has continued to expand its tools for sequence analysis, vector design, and molecular cloning. If you haven’t used our FREE software yet, check out why scientists are buzzing about it: www.vectorbee.com/en/ 🐝
January 21, 2026 at 5:51 PM
You spoke. We listened. New Updates. 🧬
Since launching in 2024, VectorBee has continued to expand its tools for sequence analysis, vector design, and molecular cloning. If you haven’t used our FREE software yet, check out why scientists are buzzing about it: www.vectorbee.com/en/ 🐝
Since launching in 2024, VectorBee has continued to expand its tools for sequence analysis, vector design, and molecular cloning. If you haven’t used our FREE software yet, check out why scientists are buzzing about it: www.vectorbee.com/en/ 🐝